The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Do all patients require maintenance therapy following alloSCT?
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, summarizes his talk on drug maintenance strategies post-allogeneic stem cell transplant (alloSCT) in patients with hematological malignancies. Dr Levis challenges the assumption that post-transplant maintenance is needed for all patients, as data in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) do not support this notion. The MORPHO study (NCT02997202) elucidated that not all patients with FLT3-mutant acute myeloid leukemia (AML) benefit from maintenance, but those who do can be identified using a FLT3-ITD measurable residual disease (MRD) assay. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant: Astellas, Daiichi Sankyo, Novartis.
